#pbyi

$PBYI 2018-08-24 : Transcripts- Edited Transcript of PBYI earnings conference call

[s2If !current_user_can(access_s2member_level0)] Please login to read the transcript. [lwa] [/s2If][s2If current_user_can(access_s2member_level0)]”

Q2 2018 Puma Biotechnology Inc Earnings Call

Los Angeles Aug 25, 2018 (Thomson StreetEvents) — Edited Transcript of Puma Biotechnology Inc earnings conference call or presentation Thursday, August 9, 2018 at 8:30:00pm GMT

TEXT version of…

(NYSE:PBYI) Puma Biotechnology Inc Up $12.45 Points

Puma Biotechnology Inc (NYSE:PBYI)

June 26th, 2018

With markets going up Puma Biotechnology Inc closed Tuesday up 24.36%, a $12.45 increase to close on $63.55. In addition to finishing higher, trading volumes were solid at 852% of normal which can indicate investors see opportunities. Be aware that the Altman Z-Score1 (An indicator of the probability for a 2-year bankruptcy) is below the…

Positions currently existing in SHORT on 2018-01-30 : $PLAY,$PBYI,$BABY,$AYI,$ABM The SHORT strategy trades SHORT on stocks. Stocks which break down below key levels become stocks of interest for this strategy. The stops are tightened on a daily basis. The target is also initaited as the trade is taken. The new trades added to SHORT are below. Much more details of the trade can be viewed inside…

Positions currently existing in SHORT on 2018-01-28 : $PLAY,$PBYI,$BABY,$AYI,$ABM The SHORT strategy trades SHORT on stocks. Stocks which break down below key levels become stocks of interest for this strategy. The stops are tightened on a daily basis. The target is also initaited as the trade is taken. The new trades added to SHORT are below. Much more details of the trade can be viewed inside…

PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other Events

PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other EventsItem 8.01 Other Events. On January 6, 2017, Puma Biotechnology, Inc. (the “Company”) announced that it expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). The cohort that has…

Credit Suisse expects that biotech stocks will see the most promotions in the coming rebalance of the Russell Indexes.

Source: Isis Pharmaceuticals, Other Biotech Stocks That Could Have Big Upside Before Russell Index Changes (NASDAQ: ISIS) – 24/7 Wall St.

Puma Biotechnology Inc. had its biggest two-day gain in seven months after data on a competitor magazine did nothing to diminish analyst’s expectations.